These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27749559)

  • 1. Cardiac device implantation in Fabry disease: A retrospective monocentric study.
    Sené T; Lidove O; Sebbah J; Darondel JM; Picard H; Aaron L; Fain O; Zenone T; Joly D; Charron P; Ziza JM
    Medicine (Baltimore); 2016 Oct; 95(40):e4996. PubMed ID: 27749559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy.
    Vijapurapu R; Geberhiwot T; Jovanovic A; Baig S; Nordin S; Kozor R; Leyva F; Kotecha D; Wheeldon N; Deegan P; Rusk RA; Moon JC; Hughes DA; Woolfson P; Steeds RP
    Heart; 2019 Dec; 105(23):1825-1831. PubMed ID: 31446426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry Cardiomyopathy.
    Weidemann F; Maier SK; Störk S; Brunner T; Liu D; Hu K; Seydelmann N; Schneider A; Becher J; Canan-Kühl S; Blaschke D; Bijnens B; Ertl G; Wanner C; Nordbeck P
    Am J Cardiol; 2016 Jul; 118(2):264-74. PubMed ID: 27265676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy.
    Vijapurapu R; Bradlow W; Leyva F; Moon JC; Zegard A; Lewis N; Kotecha D; Jovanovic A; Hughes DA; Woolfson P; Steeds RP; Geberhiwot T
    Orphanet J Rare Dis; 2022 Jan; 17(1):6. PubMed ID: 34991670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
    Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
    Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy.
    Francia P; Santini D; Musumeci B; Semprini L; Adduci C; Pagannone E; Proietti G; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2014 Nov; 25(11):1180-7. PubMed ID: 25066044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complications of permanent cardiac pacing in patients with persistent left superior vena cava.
    Polewczyk A; Kutarski A; Czekajska-Chehab E; Adamczyk P; Boczar K; Polewczyk M; Janion M
    Cardiol J; 2014; 21(2):128-37. PubMed ID: 24526508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy.
    Wang W; Lian Z; Rowin EJ; Maron BJ; Maron MS; Link MS
    Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28314849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Pacemaker and Implantable Cardioverter-Defibrillator Registry of the Italian Association of Arrhythmology and Cardiac Pacing - Annual report 2018].
    Proclemer A; Zecchin M; D'Onofrio A; Boriani G; Ricci RP; Rebellato L; Ghidina M; Bianco G; Bernardelli E; Miconi A; Zorzin AF; Gregori D
    G Ital Cardiol (Rome); 2020 Feb; 21(2):157-169. PubMed ID: 32051640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Pacemaker and Implantable Cardioverter-Defibrillator Registry of the Italian Association of Arrhythmology and Cardiac Pacing - Annual report 2015].
    Proclemer A; Zecchin M; D'Onofrio A; Boriani G; Botto GL; Facchin D; Rebellato L; Ghidina M; Bianco G; Bernardelli E; Pucher E; Gregori D
    G Ital Cardiol (Rome); 2017 Jan; 18(1):67-79. PubMed ID: 28287212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arrhythmias in Fabry cardiomyopathy.
    Acharya D; Robertson P; Kay GN; Jackson L; Warnock DG; Plumb VJ; Tallaj JA
    Clin Cardiol; 2012 Dec; 35(12):738-40. PubMed ID: 22886820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice.
    Vijapurapu R; Kozor R; Hughes DA; Woolfson P; Jovanovic A; Deegan P; Rusk R; Figtree GA; Tchan M; Whalley D; Kotecha D; Leyva F; Moon J; Geberhiwot T; Steeds RP
    Trials; 2019 May; 20(1):314. PubMed ID: 31151481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Pacemaker and Implantable Cardioverter-Defibrillator Registry of the Italian Association of Arrhythmology and Cardiac Pacing - Annual report 2017].
    Proclemer A; Zecchin M; D'Onofrio A; Ricci RP; Boriani G; Rebellato L; Ghidina M; Bianco G; Bernardelli E; Miconi A; Zorzin AF; Gregori D
    G Ital Cardiol (Rome); 2019 Mar; 20(3):136-148. PubMed ID: 30821295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The Pacemaker and Implantable Cardioverter-Defibrillator Registry of the Italian Association of Arrhythmology and Cardiac Pacing - Annual report 2016].
    Proclemer A; Zecchin M; D'Onofrio A; Boriani G; Facchin D; Rebellato L; Ghidina M; Bianco G; Bernardelli E; Pucher E; Gregori D
    G Ital Cardiol (Rome); 2018 Feb; 19(2):119-131. PubMed ID: 29531385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of pacemaker and ICD implantation in
    Ollila LH; Nikus K; Parikka H; Weckström S; Tiina H
    Open Heart; 2021 Apr; 8(1):. PubMed ID: 33893211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death].
    Lelakowski J; Pudło J; Lelakowska-Pieła M; Rydlewska A; Piekarz J; Domaracki D
    Pol Merkur Lekarski; 2016 Apr; 40(238):216-22. PubMed ID: 27137820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertrophic cardiomyopathy: the importance of arrhythmic events in patients at risk for sudden cardiac death.
    Medeiros Pde T; Martinelli Filho M; Arteaga E; Costa R; Siqueira S; Mady C; Piegas LS; Ramires JA
    Arq Bras Cardiol; 2006 Nov; 87(5):649-57. PubMed ID: 17221043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Device-Detected Nonsustained Ventricular Tachycardia in the Risk Stratification of Hypertrophic Cardiomyopathy.
    Viswanathan K; Suszko AM; DAS M; Jackson N; Gollob M; Cameron D; Spears D; Woo A; Rakowski H; Khurana M; Chauhan VS
    Pacing Clin Electrophysiol; 2016 Jul; 39(7):642-51. PubMed ID: 27027856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.